Curapel, a Cardiff, Wales, UK-based healthcare company, raised £350k in equity funding.
Backers included Finance Wales (£250k), Lancaster Capital and another investor.
The company is using the funds to to develop and commercialise its Histimex, Melidex and Olidex products.
Founded as a spinout from the University of Manchester by Chief Technology Officer Dr Neil Gibbs and led by Chief Executive Officer Dr Peter Luebcke, Curapel develops innovative new treatments for eczema and psoriasis as well as skin pigmentation conditions. Formulated from safe, natural and GRAS-designated ingredients, the company’s products are patent protected and all in late-stage product development, with clinical testing set to continue through 2016.
– Histimex, an oral treatment that has shown early clinical potential in eczema and atopic dermatitis and also has commercial potential as a treatment for paediatric eczema.
– Melidex, a cosmetic product designed to even skin tone and treat pigmentation conditions, and
– Olidex, a topical treatment for psoriasis.